Congress Materials – American Thoracic Society (ATS 2024)
2024 American Thoracic Society | May 20-22 | San Diego, CA
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Effect on exercise capacity and long-term safety and tolerability of macitentan and tadalafil as a single-tablet combination in patients with pulmonary arterial hypertension from the A DUE open-label interim analysis
Kelly M. Chin, Pavel Jansa, Ekkehard Grünig, Jakob A. Hauser, Verena Walter, Michael Friberg, Hany Rofael, Fenling Fan
Efficacy and Safety of Tadalafil and Sildenafil in Pulmonary Arterial Hypertension: Results of a Systematic Literature Review
R. Saggar, N. Rahhali, A. Senatore, M. Sandros, D. Lopez, G. Gomez Rendon, A. Khan, A. Wright, E. Boulton, S. Sahay
Expert Consensus on Best Practices for Oral Selexipag Titration and Management of Expected Side Effects (SE) in the Treatment of Pulmonary Arterial Hypertension (PAH)
Sheryl Wu , Gurinderpal Doad, Christina Benninger, Michelle Cho, Richard Perry, Daisy Bridge, Charlotte Oswald, Luis Val-Maranes, Paul Strachan
Optimising Thresholds for the Detection of Pulmonary Hypertension (PH) and Pre-capillary PH Using Automatic Measurement of TRJV on Echocardiography
Mahan Salehi, Samer Alabed, Michael Sharkey, Ahmed Maiter, Krit Dwivedi, Tarik Yardibi, Mona Selej, Abdul Hameed, Athanasios Charalampopoulos, David G Kiely, Andrew J Swift
Pre-planned study design adaptations in UNISUS: a Phase 3, Conclusions randomized superiority study comparing the efficacy, safety and tolerability of macitentan 75 mg versus 10 mg in patients with pulmonary arterial hypertension (PAH)
Vallerie McLaughlin, Yuichi Tamura, Marc Humbert, Arthur Backer, Neli Boyanova, Hilke Kracker, Anna Larbalestier, Lilian Sanna, Marius Hoeper
Provider preferences regarding the use of combination ERA+PDE5i for the treatment of pulmonary arterial hypertension: Results from a discrete choice experiment.
Nicholas A Kolaitis, Martha Kingman, Melisa Wilson, Gabriela Gomez Rendon, David Lopez, Mohammad Rahman, Carly J Paoli, Ashley Martin, November McGarvey, Abraham Lee, & Lana Melendres
Selexipag in pulmonary arterial hypertension associated with connective tissue disease (PAH-CTD): real-world evidence from EXPOSURE
Gaine S, Escribano-Subias P, Muller A3, Fernandes CC, Fontana M, Remenova T, Söderberg S, Lange TJ
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.